AXQ Capital LP Takes Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

AXQ Capital LP acquired a new position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 18,126 shares of the biopharmaceutical company’s stock, valued at approximately $171,000.

A number of other hedge funds have also bought and sold shares of the business. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Amicus Therapeutics in the third quarter worth approximately $55,000. R Squared Ltd bought a new stake in Amicus Therapeutics in the 4th quarter worth approximately $79,000. KBC Group NV raised its stake in Amicus Therapeutics by 44.4% during the 4th quarter. KBC Group NV now owns 10,154 shares of the biopharmaceutical company’s stock valued at $96,000 after buying an additional 3,120 shares during the last quarter. Sciencast Management LP bought a new position in shares of Amicus Therapeutics during the 4th quarter valued at $100,000. Finally, Stephens Inc. AR purchased a new position in shares of Amicus Therapeutics in the 4th quarter worth $101,000.

Amicus Therapeutics Price Performance

NASDAQ:FOLD opened at $8.69 on Tuesday. The business’s 50-day simple moving average is $9.34 and its two-hundred day simple moving average is $10.04. Amicus Therapeutics, Inc. has a 52 week low of $8.55 and a 52 week high of $12.65. The stock has a market cap of $2.67 billion, a PE ratio of -48.28, a P/E/G ratio of 1.51 and a beta of 0.69. The company has a quick ratio of 2.42, a current ratio of 3.39 and a debt-to-equity ratio of 2.01.

Analyst Ratings Changes

A number of research firms recently commented on FOLD. Cantor Fitzgerald reiterated an “overweight” rating and set a $21.00 price objective on shares of Amicus Therapeutics in a research report on Wednesday, January 15th. StockNews.com cut shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, February 20th. Wells Fargo & Company cut their target price on shares of Amicus Therapeutics from $18.00 to $17.00 and set an “overweight” rating for the company in a research report on Thursday, February 20th. Needham & Company LLC reiterated a “hold” rating on shares of Amicus Therapeutics in a research report on Thursday, February 20th. Finally, Morgan Stanley reissued an “equal weight” rating and set a $12.00 price objective (down previously from $17.00) on shares of Amicus Therapeutics in a research report on Friday, December 13th. Three analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $16.75.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.